Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults

  • Technology appraisal guidance
  • TA157
  • Published: 
Download guidance (PDF)

8 Sources of evidence considered by the Committee

The Evidence Review Group (ERG) report for this appraisal was prepared by the School of Health and Related Research, University of Sheffield:

  • Holmes M, Caroll C, Papaioannou D, Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: A Single Technology Appraisal, May 2008.

The following organisations accepted the invitation to participate in this appraisal. They were invited to comment on the draft scope. Manufacturers, or sponsors, were also invited to make written submissions. Professional or specialist and patient or carer groups gave their expert views on dabigatran by providing a written statement to the Committee. Manufacturers, or sponsors, and professional or specialist and patient or carer groups have the opportunity to appeal against the final appraisal determination.

Manufacturer or sponsor:

  • Boehringer Ingelheim (dabigatran)

Professional or specialist and patient or carer groups:

  • Anticoagulation Europe

  • British Association for Surgery of the Knee

  • British Haematology Society

  • British Orthopaedic Association

  • British Society for Haemostasis and Thrombosis

  • British Thoracic Society

  • DVT Awareness Campaign

  • Lifeblood: The Thrombosis Charity

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians

Other consultees

  • Department of Health

  • Welsh Assembly Government

Commentator organisations (did not provide written evidence and without the right of appeal)

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • GlaxoSmithKline (fondaparinux sodium)

  • National Collaborating Centre for Acute Care

  • National Coordinating Centre for Health Technology Assessment

  • NHS Quality Improvement Scotland

  • Pfizer (dalteparin sodium)

  • sanofi-aventis (enoxaparin sodium)

  • School of Health & Related Research Sheffield (ScHARR)

The following individuals were selected from clinical specialist and patient advocate nominations from the non-manufacturer/sponsor consultees and commentators. They gave their expert personal view on dabigatran by providing oral evidence to the Committee.

  • Professor Roger Atkins, consultant orthopaedic surgeon, nominated by the British Orthopaedic Association – clinical specialist

  • Mrs Diane Eaton, nominated by Anticoagulation Europe (ACE) – patient expert